翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03378 翰思艾泰-B

午间休市 12-23 11:59:57

18.250

-13.750

-42.97%

最高29.480	最低18.070	成交量628.60万
今开28.900	昨收32.000	日振幅35.66%
总市值24.86亿	流通市值24.86亿	总股本1.36亿
成交额1.67亿	换手率4.61%	流通股本1.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03378","market":"HK","secType":"STK","nameCN":"翰思艾泰-B","latestPrice":18.25,"timestamp":1766462397692,"preClose":32,"halted":0,"volume":6286000,"delay":0,"floatShares":136218830,"shares":136218830,"eps":0,"marketStatus":"午间休市","change":-13.75,"latestTime":"12-23 11:59:57","open":28.9,"high":29.48,"low":18.07,"amount":166690401,"amplitude":0.356563,"askPrice":18.25,"askSize":2200,"bidPrice":18.18,"bidSize":1900,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766466000000},"marketStatusCode":3,"adr":0,"listingDate":1766419200000,"exchange":"SEHK","adjPreClose":32,"openAndCloseTimeList":[[1766453400000,1766462400000],[1766466000000,1766476800000]],"volumeRatio":0,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000905","market":"SZ","secType":"STK","nameCN":"厦门港务","latestPrice":13.89,"timestamp":1766464812000,"preClose":13.43,"halted":0,"volume":61451400,"delay":0,"premium":"+18.59"}},"requestUrl":"/m/hq/s/03378","defaultTab":"news","newsList":[{"id":"2593639194","title":"武汉又冲出一个医药IPO！60岁武大学霸带队","url":"https://stock-news.laohu8.com/highlight/detail?id=2593639194","media":"创业邦","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593639194?lang=zh_cn&edition=full","pubTime":"2025-12-23 11:23","pubTimestamp":1766460221,"startTime":"0","endTime":"0","summary":"翰思艾泰正在研发用于癌症及自身免疫疾病精准治疗的创新药，解决该领域未被满足的医疗需求。01湖北农村走出的IPO敲钟人现年60岁的张发明，出生在湖北天门石家河镇的一个普通农村家庭，16岁时考入武汉大学物理化学专业，是家中第一个走出乡村的大学生。以此为平台，张发明正式进军创新药研发。HX009是一款PD-1/SIRPα双功能抗体融合蛋白，其设计旨在同时阻断PD-1免疫抑制信号和CD47-SIRPα介导的免疫逃逸信号，从而协同激活T细胞和巨噬细胞，对抗肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223112437a6c409fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223112437a6c409fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","BK1515","09939","BK1161","BK1574","03378","BK1535"],"gpt_icon":1},{"id":"2593946824","title":"港股不行了？今天这家新药上市又是大跌30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593946824","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593946824?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:47","pubTimestamp":1766458020,"startTime":"0","endTime":"0","summary":"2025年12月23日，湖北武汉的翰思艾泰生物科技(武汉)股份有限公司在港交所上市，大跌30%。本次发行1832.1万股，发行价32港元/股，规模约5.9亿港元（约合7500万美元）。公司有核心产品HX009（PD-1/SIRPα双功能抗体融合蛋白）、两款主要产品HX044及HX301，还有7项临床前阶段候选药物。其定位是提供新一代肿瘤免疫治疗、一流ADC分子及新型自身免疫治疗。2023年、2024年和2025年前八个月，公司研发开支分别为4666.3万、7472.1万和5617.8万元，净亏损分别为0.85亿、1.17亿和0.88亿元。文中未提及投资机构、财务顾问及融资目的。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223110617a46cf17e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223110617a46cf17e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","03378","BK1535"],"gpt_icon":0},{"id":"2593452767","title":"翰思艾泰港交所上市破发跌9%，总市值39.6亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593452767","media":"瑞财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593452767?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:34","pubTimestamp":1766453667,"startTime":"0","endTime":"0","summary":"12月23日，翰思艾泰-B（03378.HK）在港交所挂牌上市，独家保荐人为工银国际，开盘跌9.25%，总市值39.56亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223093442a46c8f30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223093442a46c8f30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1535","BK1173"],"gpt_icon":0},{"id":"1116178869","title":"异动解读 | 翰思艾泰-B首日盘中大跌9.56%，高风险管线与财务隐忧引发抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1116178869","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116178869?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:32","pubTimestamp":1766453552,"startTime":"0","endTime":"0","summary":"翰思艾泰-B今日首日挂牌交易，盘中股价一度大跌9.56%，开盘报28.9港元，较发行价32港元低开9.69%。消息面上，翰思艾泰的核心产品HX009是全球唯一靶向PD-1与CD47的双抗药物，但CD47靶点因严重血液毒性风险被国际药企普遍放弃，其管线尚未跨过临床II期\"死亡谷\"，商业化前景存疑。公司近年净亏损持续扩大，2025年前8个月亏损同比增超80%，且存在对赌协议压力，若2026年底前未达里程碑或触发大额赎回。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03378"],"gpt_icon":0},{"id":"2593268452","title":"新股首日 | 翰思艾泰-B(03378)首挂上市 早盘低开9.69% 核心产品HX009正在中国进行三个临床项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2593268452","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593268452?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:25","pubTimestamp":1766453142,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰思艾泰-B首挂上市，公告显示，每股定价32港元，共发行1832.1万股股份，每手100股，所得款项净额约5.31亿港元。截至发稿，跌9.69%，报28.9港元，成交额7566.97万港元。公开资料显示，翰思艾泰的核心产品HX009是一种同时靶向CD47及PD-1的双特异性抗体融合蛋白。根据弗若斯特沙利文报告，截至最后实际可行日期，HX009的临床试验进展在同类CD47靶向双特异性抗体/双功能融合蛋白产品中处于全球领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03378","BK1173","BK1535"],"gpt_icon":1},{"id":"1140374296","title":"翰思艾泰-B股票将在香港首次公开交易时以每股28.9港元开盘，较发行价32港元有所下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1140374296","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140374296?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:24","pubTimestamp":1766453097,"startTime":"0","endTime":"0","summary":"翰思艾泰-B股票将在香港首次公开交易时以每股28.9港元开盘，较发行价32港元有所下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1173","BK1535","03378"],"gpt_icon":0},{"id":"2593459806","title":"三只新股同日暗盘！最高大涨超275%，一手赚超1.1万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593459806","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593459806?lang=zh_cn&edition=full","pubTime":"2025-12-23 07:29","pubTimestamp":1766446140,"startTime":"0","endTime":"0","summary":"　　12月22日，港股三只新股暗盘同时开启，行情走势却呈现冰火两重天。　　整体而言，三只新股的表现差异与其所处赛道的近期行情关系密切。其中，专注于人工智能产业化应用的诺比侃，暗盘股价大涨275.75%；提供数字综合健康服务及健康保险解决方案的轻松健康，暗盘亦大涨127.95%；但创新药赛道的翰思艾泰-B却表现平平，暗盘最终仅录得2.06%的涨幅。　　富途暗盘数据显示，诺比侃暗盘收涨275.75%，报300.60港元/股，每手50股，不计手续费，一手赚11030港元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-12-23/doc-inhctsyw1032451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AI","BK4528","BK1173","BK4587","BK4551","02635","BK4585","BK4023","03378","BK4588","02661","BK4543","BK1535"],"gpt_icon":1},{"id":"2593945584","title":"港股IPO动态：今日翰思艾泰、轻松健康、诺比侃上市，壁仞科技等7股申购","url":"https://stock-news.laohu8.com/highlight/detail?id=2593945584","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593945584?lang=zh_cn&edition=full","pubTime":"2025-12-23 06:14","pubTimestamp":1766441665,"startTime":"0","endTime":"0","summary":"格隆汇12月23日｜今日翰思艾泰-B(3378.HK)、轻松健康(2661.HK)、诺比侃(2635.HK)上市，壁仞科技(6082.HK)、卧安机器人(6600.HK)、英硅智能(3696.HK)、美联股份(2671.HK)、五一视界(6651.HK)、迅策(3317.HK)及林清轩(2657.HK)申购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223061513a6c2f5df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223061513a6c2f5df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03696","BK1173","BK1535","03378"],"gpt_icon":0},{"id":"2593481657","title":"新股暗盘 | 翰思艾泰-B(03378)暗盘收跌14.81% 每手亏474港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593481657","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593481657?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:07","pubTimestamp":1766401627,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰思艾泰-B(03378)将于12月23日(周二)在香港挂牌。截至收盘，利弗莫尔证券暗盘交易显示报价27.26港元，较招股价32港元下跌14.81%，每手100股，不计手续费，每手亏474港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251222/31881890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1535","BK1173","03378"],"gpt_icon":0},{"id":"1125083194","title":"老虎暗盘 | 翰思艾泰暗盘大涨25%，一手账面赚824港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125083194","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125083194?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:15","pubTimestamp":1766391312,"startTime":"0","endTime":"0","summary":"明日挂牌的翰思艾泰-B暗盘大涨25%，不计手续费，一手100股账面赚824 港元。尚未盈利的生物科技公司翰思艾泰-B 12月15日至18日招股。翰思艾泰计划发行1832.1万股H股，一成于香港作公开发售，招股价介乎28港元至32港元，集资最多5.9亿港元。","market":"us","thumbnail":"https://community-static.tradeup.com/news/69cc6865fcca77ca761fb46e6b686d77","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/69cc6865fcca77ca761fb46e6b686d77"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"gpt_icon":0},{"id":"2593125173","title":"厦门港务：关于深圳证券交易所《关于厦门港务发展股份有限公司发行股份购买资产并募集配套资金申请的审核问询函》的回复(修订稿)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593125173","media":"深圳交易所","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593125173?lang=zh_cn&edition=full","pubTime":"2025-12-21 13:27","pubTimestamp":1766294837,"startTime":"0","endTime":"0","summary":"厦门港务 (000905)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251221133846a6bc8a86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251221133846a6bc8a86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1535","03378","BK1173"],"gpt_icon":0},{"id":"2592124927","title":"新股消息 | 翰思艾泰-B(03378)招股结束 孖展认购额录得1472.9亿港元 超购2511倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2592124927","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592124927?lang=zh_cn&edition=full","pubTime":"2025-12-18 14:34","pubTimestamp":1766039696,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物科技公司翰思艾泰-B于12月15日至12月18日招股，最新已结束招股。根据市场消息，翰思艾泰已获券商借出1472.9亿港元孖展，以公开发售集资额5863万港元计，超购2511倍。翰思艾泰计划发行1832.1万股H股，其中香港公开发售占10%。每股发售价介于28至32港元，每手100股，一手入场费3232.3港元，募资总额最多5.9亿港元。财务方面，于往绩记录期间，翰思艾泰并无盈利，并录得经营亏损。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"新股消息 | 翰思艾泰-B(03378)招股结束 孖展认购额录得1472.9亿港元 超购2511倍","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1173","03378","BK1535"],"gpt_icon":0},{"id":"2592925492","title":"【新股IPO】国投证券国际：翰思艾泰-B(03378)临床开发领域具备自主核心技术 予IPO专用评分5.7","url":"https://stock-news.laohu8.com/highlight/detail?id=2592925492","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592925492?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:07","pubTimestamp":1766027259,"startTime":"0","endTime":"0","summary":"翰思艾泰是一家在结构生物学、转化医学及临床开发领域具备自主核心技术与丰富经验的生物科技企业，目前布局有三款肿瘤领域临床阶段候选药物及七款临床前阶段在研药物。核心产品HX009是全球首创及唯一临床开发的PD-1/CD47双特异性抗体及双功能融合蛋白。考虑公司研发管线、港股医药打新市场火热等核心因素，该机构给予公司IPO专用评分“5.7”。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/ZmY5NDVmYTUwNTRiZmQzZTdjNTQyNTY4MjUwMzQ=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZmY5NDVmYTUwNTRiZmQzZTdjNTQyNTY4MjUwMzQ=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971786","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1535","161027","BK1173","03378"],"gpt_icon":1},{"id":"1183465059","title":"PD-1耐药后的王炸IO，起飞了","url":"https://stock-news.laohu8.com/highlight/detail?id=1183465059","media":"潮药Bar","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183465059?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:10","pubTimestamp":1765962634,"startTime":"0","endTime":"0","summary":"能够在下一个时代里，掀起惊涛骇浪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/qybe22FM2zrKxJr6n31ECg","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1765962698252","symbols":["03378"],"gpt_icon":0},{"id":"1122065346","title":"新一代颠覆级Biotech，潜力爆炸","url":"https://stock-news.laohu8.com/highlight/detail?id=1122065346","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122065346?lang=zh_cn&edition=full","pubTime":"2025-12-17 13:24","pubTimestamp":1765949096,"startTime":"0","endTime":"0","summary":"诺奖级创新，下一代IO核心管线","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/iYX1HVVBO874JduTwtsR2w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1595830015846","symbols":["03378"],"gpt_icon":1},{"id":"2592795703","title":"【新股IPO】国元国际：瀚思艾泰-B(03378)CD47/PD-1双特异性抗体具备独特性 建议谨慎申购","url":"https://stock-news.laohu8.com/highlight/detail?id=2592795703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592795703?lang=zh_cn&edition=full","pubTime":"2025-12-17 10:55","pubTimestamp":1765940103,"startTime":"0","endTime":"0","summary":"2023 年5月获FDA批准开展 HX009 Ib/II 期治疗 DLBCL 研究。公司的管线有独特的竞争优势，截至2025年12 月 1 日，全球无已获批的 CD47/PD-1 双特异性抗体产品，HX009在该靶点组合中处于唯一性地位。上市后市值在 38.14-43.59 亿港元，但考虑到公司的 CD47/PD-1 双特异性抗体有一定的独特性，如果上市之后，产品有较大的潜力，建议谨慎申购。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/NWEyNjUzNmNkZDE2ZjIxMDg2ODEwOTExNzY3Nw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWEyNjUzNmNkZDE2ZjIxMDg2ODEwOTExNzY3Nw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971704","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU1169590202.USD","BK1535","03378","PD","LU1169589451.USD","BK1173"],"gpt_icon":1},{"id":"2592912699","title":"翰思艾泰启动港股IPO 推出靶向Tregs新一代免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2592912699","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592912699?lang=zh_cn&edition=full","pubTime":"2025-12-17 08:53","pubTimestamp":1765932783,"startTime":"0","endTime":"0","summary":"翰思艾泰于12月15日开启港交所18A章上市招股，成为2025年备受关注的新一代Biotech企业。公司核心管线聚焦调节性T细胞调控，布局多款创新机制药物。HX044已获国内联用PD-1抑制剂临床批件。翰思艾泰作为少数拥有两款MCE临床阶段管线的公司之一，具备较强对外授权可能性。BioNTech、和铂医药、中生制药等企业亦在推进靶向TME中Tregs的新型CTLA-4疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085812a4546592&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085812a4546592&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1173","BK1535"],"gpt_icon":0},{"id":"1183827692","title":"新股招股｜翰思艾泰-B今日起招股，一手入场费3232.27港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183827692","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183827692?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:08","pubTimestamp":1765768110,"startTime":"0","endTime":"0","summary":"12月15日，$翰思艾泰-B $ 发布公告，于12月15日-12月18日招股，公司拟全球发售约1832.1万股股份，预期将于12月23日上市。申购阶梯：每手100股，入场费3232.27港元。乙组门槛为30万股，申购所需资金约969.68万港元。于往绩记录期间及直至最后实际可行日期，公司已在澳大利亚及中国完成HX009的I期临床试验。","market":"hk","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股｜翰思艾泰-B今日起招股，一手入场费3232.27港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"gpt_icon":1},{"id":"2591672876","title":"翰思艾泰-B12月15日至12月18日招股 预计12月23日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591672876","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591672876?lang=zh_cn&edition=full","pubTime":"2025-12-15 07:03","pubTimestamp":1765753380,"startTime":"0","endTime":"0","summary":"翰思艾泰-B(03378)于2025年12月15日至12月18日招股，该公司拟全球发售1832.1万股，其中香港发售占10%，国际发售占90%，每股发售价28-32港元。每手100股，预期股份将于2025年12月23日在联交 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251215/c673194912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["03378"],"gpt_icon":0},{"id":"2590457696","title":"创新药企扎堆港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590457696","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590457696?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:45","pubTimestamp":1765525500,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　12月以来，港股生物医药板块IPO市场热度持续攀升：嘉和生物、翰思艾泰、明基医院、华生物相继通过聆讯，和美药业、高光制药、石药创新、君赛生物陆续递交上市申请，中国证监会国际合作司亦于近期披露英硅智能境外发行上市的备案通知书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-12/doc-inhaprxm5183321.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-12/doc-inhaprxm5183321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03378","159992","BK1574","BK1161","06978"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hanxbio.com/","stockEarnings":[{"period":"1week","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0231},{"period":"3month","weight":-0.0137},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3084},{"period":"ytd","weight":0.2862}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰思艾泰生物医药科技(武汉)股份有限公司成立于2014年,是一家专注于结构生物学、转化医学及临床开发的创新型生物科技公司。公司致力于开发新一代免疫疗法,为全球患者提供可负担、安全且高效的医疗解决方案,以应对重大疾病挑战。秉持创新驱动的使命与愿景,翰思艾泰专注于发现、研发和商业化用于癌症及自身免疫疾病精准治疗的产品,努力满足全球未被满足的医疗需求,推动疾病的预防、控制和减少,为全球健康事业贡献力量。\n公司科研与管理团队拥有多年在国家重点科研机构及跨国药企从事欧美新药研发、产业化实施和管理的丰富经验。在武汉、杭州、上海、香港、圣地亚哥及澳大利亚,公司已组建了从药物发现到临床研究的完整管理团队,并搭建了拥有全球专利的高亲和力、长半衰期抗体筛选平台,以及肿瘤靶向Geographical Positioning Smallmolecule-Antibody(GPSmAb)创新技术平台。\n目前,翰思艾泰已建立了聚焦肿瘤及免疫疾病的自主创新药物产品管线,并积极开展国际合作项目,为实现全球健康贡献力量。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.005427},{"month":2,"riseRate":0.411765,"avgChangeRate":0.008835},{"month":3,"riseRate":0.352941,"avgChangeRate":-0.021319},{"month":4,"riseRate":0.705882,"avgChangeRate":0.100651},{"month":5,"riseRate":0.352941,"avgChangeRate":0.046508},{"month":6,"riseRate":0.470588,"avgChangeRate":-0.00883},{"month":7,"riseRate":0.470588,"avgChangeRate":0.004276},{"month":8,"riseRate":0.470588,"avgChangeRate":-0.031033},{"month":9,"riseRate":0.588235,"avgChangeRate":-0.013577},{"month":10,"riseRate":0.75,"avgChangeRate":0.019136},{"month":11,"riseRate":0.625,"avgChangeRate":0.009468},{"month":12,"riseRate":0.625,"avgChangeRate":0.056179}],"exchange":"SEHK","name":"翰思艾泰-B","nameEN":"HANXBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰思艾泰-B,03378,翰思艾泰-B股票,翰思艾泰-B股票老虎,翰思艾泰-B股票老虎国际,翰思艾泰-B行情,翰思艾泰-B股票行情,翰思艾泰-B股价,翰思艾泰-B股市,翰思艾泰-B股票价格,翰思艾泰-B股票交易,翰思艾泰-B股票购买,翰思艾泰-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}